Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024

Company Overview - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing an innovative pipeline of cancer therapies [3] - The company's notable pipeline includes revumenib, a selective menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody targeting the colony stimulating factor 1 (CSF-1) receptor [3] Upcoming Event - The company will host an in-person investor event and live webcast on December 9, 2024, at 7:00 a.m. PT/10:00 a.m. ET during the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, California [1] - Members of the Syndax management team will be joined by key opinion leaders to discuss data updates from the revumenib and Niktimvo™ programs [1] Webcast Availability - A live webcast of the event will be accessible on the investor section of the company's website, with a replay available for a limited time [2]